


**OMTO, Volume 18**

## **Supplemental Information**

### **Route of 41BB/41BBL Costimulation Determines**

### **Effector Function of B7-H3-CAR.CD28 $\zeta$ T Cells**

**Phuong Nguyen, Emmanuel Okeke, Michael Clay, Dalia Haydar, Julie Justice, Carla O'Reilly, Shondra Pruett-Miller, James Papizan, Jennifer Moore, Sheng Zhou, Robert Thom, Giedre Krenciute, Stephen Gottschalk, and Christopher DeRenzo**



**Supplementary Figure 1. Normal tissue staining by IHC.** An adult normal tissue microarray was stained for B7-H3 by IHC. H-scores for normal tissue specimens with less than 3 samples available are depicted.

RED: Leader Sequence  
BLUE: scFv MGA271 vH  
GREY: scFv linker  
BLUE: scFv MGA271 vL

ORANGE: Hinge/Transmembrane  
PINK: Costimulatory Domain  
BLACK: CD3 $\zeta$

### CD8 $\alpha$ /CD28

MDWIWRILFLVGAATGAHSEVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSDSSAIY  
YADTVKGRFTISRDNAKNSLYLQMNLSRDEDTAVYYCGRGRENIYYGSRLDYWGQGTTVTVSSGGGGSGGGSGGGGS  
DIQLTQSPSFLSASVGDVRTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRYSVPSRFSGSGSGTDFTLTISSL  
QPEDFATYYCQQYNNYPFTFGQGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIW  
APLAGTCGVLLLSLVITLYCRSKRSRLHSDYMNMTPRRPGPTRKHYPYAPPRDFAAYRSRVKFSRSADAPAYQQGQ  
NQLYNELNLRREEYDVLDKRRGRDPPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRRGKGGHDGLYQGLST  
ATKDTYDALHMQUALPPR

### CD8 $\alpha$ /41BB

MDWIWRILFLVGAATGAHSEVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSDSSAIY  
YADTVKGRFTISRDNAKNSLYLQMNLSRDEDTAVYYCGRGRENIYYGSRLDYWGQGTTVTVSSGGGGSGGGSGGGGS  
DIQLTQSPSFLSASVGDVRTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRYSVPSRFSGSGSGTDFTLTISSL  
QPEDFATYYCQQYNNYPFTFGQGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIW  
APLAGTCGVLLLSLVITLYCKRGRKLLYIFKQPFMRPVQTTQEEDGCSCRFPPEEEEGGCELRVKFSRSADAPAYQQG  
QNQLYNELNLRREEYDVLDKRRGRDPPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRRGKGGHDGLYQGLS  
TATKDTYDALHMQUALPPR

### CD28/CD28

MDWIWRILFLVGAATGAHSEVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSDSSAIY  
YADTVKGRFTISRDNAKNSLYLQMNLSRDEDTAVYYCGRGRENIYYGSRLDYWGQGTTVTVSSGGGGSGGGSGGGGS  
DIQLTQSPSFLSASVGDVRTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRYSVPSRFSGSGSGTDFTLTISSL  
QPEDFATYYCQQYNNYPFTFGQGTKLEIKIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLPFGPSKPFVWLVVVG  
LACYSLLVTVAFIIFWVRSKRSRLHSDYMNMTPRRPGPTRKHYPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQL  
YNELNLRREEYDVLDKRRGRDPPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRRGKGGHDGLYQGLSTAT  
KDTYDALHMQUALPPR


### CD28/41BB

MDWIWRILFLVGAATGAHSEVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSDSSAIY  
YADTVKGRFTISRDNAKNSLYLQMNLSRDEDTAVYYCGRGRENIYYGSRLDYWGQGTTVTVSSGGGGSGGGSGGGGS  
DIQLTQSPSFLSASVGDVRTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRYSVPSRFSGSGSGTDFTLTISSL  
QPEDFATYYCQQYNNYPFTFGQGTKLEIKIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLPFGPSKPFVWLVVVG  
LACYSLLVTVAFIIFWVRSKRSRLHSDYMNMTPRRPGPTRKHYPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQL  
LYNELNLRREEYDVLDKRRGRDPPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRRGKGGHDGLYQGLSTAT  
KDTYDALHMQUALPPR

### CD8 $\alpha$ /A

MDWIWRILFLVGAATGAHSEVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSDSSAIY  
YADTVKGRFTISRDNAKNSLYLQMNLSRDEDTAVYYCGRGRENIYYGSRLDYWGQGTTVTVSSGGGGSGGGSGGGGS  
DIQLTQSPSFLSASVGDVRTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRYSVPSRFSGSGSGTDFTLTISSL  
QPEDFATYYCQQYNNYPFTFGQGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIW  
APLAGTCGVLLLSLVITLYCKRGR


**Supplementary Figure 2. Second generation B7-H3-CAR amino acid sequences.**



**Supplementary Figure 3. Flow cytometry for B7-H3 expression on tumor cell lines.** A known B7-H3-negative cell line KG1A (acute myeloid leukemia) served as a negative control. B7-H3 antibody was used to determine B7-H3 expression on LM7KO, LM7, A549, U373 and ffLuc-expressing cell lines.

CD8 $\alpha$ /CD28    
 CD8 $\alpha$ /41BB    
 CD8 $\alpha$ / $\Delta$   
 CD28/CD28    
 CD28/41BB    
 LM7 only

**Supplementary Figure 4. Individual donor 2G-CAR repeat killing assay.** 2G-CAR or control (CD8 $\alpha$ / $\Delta$ ) T cells were repeatedly stimulated with LM7 tumor cells at a 0.5:1 T-cell to tumor cell ratio, and cytotoxicity measured by an impedance based assay (xCelligence). Assays performed in triplicate. Dashed line represents 50% killing of target cells. The final stimulation is indicated for each donor.



**Supplementary Figure 4**

RED: Leader Sequence

BLUE: scFv MGA271 vH

GREY: scFv linker

BLUE: scFv MGA271 vL

ORANGE: CD8a Hinge/Transmembrane

PINK: CD28 Costimulatory Domain

PINK: 41BB Costimulatory Domain

BLACK: CD3 $\zeta$

GREEN: 41BB ligand

BROWN: GSG.P2A


### 3G (CD8 $\alpha$ /CD28.41BB)

MDWIWRILFLVGAATGAHSEVQLVESGGGLVQPGGSLRLSCAASGFTTFSSFGMHVWRQAPGKGLEWVAYISSDSSAIY  
YADTVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCGRGRENIYYGSRLDYWGQGTTVTVSSGGGSGGGGSGGGG  
DIQLTQSPSFLSASVGDRTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRSGVPSRFSGSGSGTDFTLTISSL  
QPEDFATYYCQQYNNYPFTFGQGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIW  
APLAGTCGVLLLSLVITLYCRSKRSRLLHSDYMNMTPRRPGPTRKHYPYAPPRDFAAYRSKRGRKLLLYIFKQPFMR  
PVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNLQYNEINLGRREEYDVLDKRRGRDPPEMGGKPRRKN  
PQEGLYNELQKDKMAEAYSEIGMKGERRRRGKGDGLYQGLSTATKDTYDALHMQALPPR

### 41BBL (41BBL.2A.CD8 $\alpha$ /CD28)


MEYASDASLDPEAPWPPAPRARACRVLPWALVAGLLLLLLLLLAAACAVFLACPWAVSGARASPGSAASPRLREGPELSP  
DDPAGLLDLRQGMFAQLVAQNVLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYVFFQLELRRVVAGE  
GSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATV  
LGLFRVTPEIPAGLPSRSEGSGATNFSLLKQAGDVEENPGPMDWIWRILFLVGAATGAHSEVQLVESGGGLVQPGG  
LRLSCAASGFTTFSSFGMHVWRQAPGKGLEWVAYISSDSSAIYYADTVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYY  
CGRGRENIYYGSRLDYWGQGTTVTVSSGGGSGGGGSGGGGSDIQLTQSPSFLSASVGDRTITCKASQNVDTNVAWY  
QQKPGKAPKALIYSASYRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPFTFGQGTKLEIKTTTPAPR  
PPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCRSKRSRLLHSDYMNMT  
PRRPGPTRKHYPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNLQYNEINLGRREEYDVLDKRRGRDPPEMGGKPRRKN  
PQEGLYNELQKDKMAEAYSEIGMKGERRRRGKGDGLYQGLSTATKDTYDALHMQALPPR

**Supplementary Figure 5. 3G and 41BBL B7-H3-CAR amino acid sequences.**



**Supplementary Figure 6. CD8 $\alpha$ /CD28-, 3G- and 41BBL-CAR transduction, expansion, and phenotype.** Transduction was determined by (A-B) VCN and CAR surface expression (N=8, one-way ANOVA), and (C) 41BBL expression (N=4). (D) T cells were grown in media plus IL-7 and IL-15, and fold expansion determined on day 9/10 post-transduction (N=8, one-way ANOVA). (E) CD4/CD8 expression and (F) memory phenotype of CAR-positive T cells. Data, mean  $\pm$  SEM; \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , ns = non-significant.


CD8 $\alpha$ /CD28 
  3G 
  41BBL 
  CD8 $\alpha$ / $\Delta$ 
 LM7 only



**Supplementary Figure 7. Individual donor CD8 $\alpha$ /CD28-, 3G- and 41BBL-CAR repeat killing assay.** CAR or control (CD8 $\alpha$ / $\Delta$ ) T cells were repeatedly stimulated with LM7 tumor cells at a 0.5:1 T-cell to tumor cell ratio, and cytolysis measured by an impedance based assay (xCelligence). Assays performed in triplicate. The dashed line represents 50% killing of target cells. The final stimulation is indicated for each donor.



## Orthotopic high grade glioma model (U373)



**Supplementary Figure 8: CD8 $\alpha$ /CD28- and 41BBL-CAR T cells have robust anti-glioma activity *in vivo*.** NSG mice received intracranial (i.c.) injection of  $5 \times 10^4$  U373.ffLuc cells on day 0, followed by  $2 \times 10^6$  CAR or control (CD8 $\alpha$ / $\Delta$ ) T cells i.c. on day 7. **(A)** Bioluminescent signal (flux = photons/second). **(B)** Kaplan-Meier survival curve for injected mice. Data, log-rank (Mantel-Cox) test; N=10 mice per group; \*\*\*\* p<0.0001.